Investigational drug · Phase 3
Gimistotug
Also called: BGB-A445
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma.
Phase 3Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
1 still active
All registered trials
4
Any phase or sponsor naming "Gimistotug"
First trial start
2019
Dec 19, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Gimistotug", any sponsor or status.
Conditions studied
As listed on its trial records.
- Urothelial Carcinoma
- Renal Cell Carcinoma
- Melanoma
- Non-mucosal Melanoma
- Non-small Cell Lung Cancer
- Metastatic Non-small Cell Lung Cancer
- Advanced Malignancies
- Non-Small Cell Lung Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Melanoma · Bladder and urothelial cancer · Kidney cancer (renal cell carcinoma) · Oncology · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Gimistotug" as an intervention, largest first.
- Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesPivotal-lookingCompleted
BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
NCT04164199 · 404 participants · Start Dec 19, 2019 · Primary completion May 23, 2026
Drug: Tislelizumab; Pamiparib and 11 more · For: Advanced Malignancies
Sites: Miami, Florida; New York, New York; Nashville, Tennessee · 106 sites in all
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT04215978 · 204 participants · Start Jan 30, 2020 · Primary completion Jan 24, 2025
Drug: BGB-A445; tislelizumab · For: Advanced Solid Tumor; Non Small Cell Lung Cancer; Head and Neck Squamous Cell Carcinoma (HNSCC) and 1 more
Sites: Los Angeles, California; San Diego, California; Pittsburgh, Pennsylvania · 30 sites in all
- A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.Active, not recruiting
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT05661955 · 113 participants · Start Jan 9, 2023 · Primary completion May 27, 2025
Drug: BGB-A445; Tislelizumab · For: Urothelial Carcinoma; Renal Cell Carcinoma; Melanoma and 1 more
Sites: Beijing, China; Fuzhou, China; Lanzhou, China · 18 sites in all
BeiGeneBeOne Medicines (BeiGene) (ONC)
NCT06029127 · 35 participants · Start Oct 23, 2023 · Primary completion Dec 31, 2024
Drug: Gimistotug; Docetaxel and 1 more · For: Non-Small Cell Lung Cancer
Sites: Beijing, China; Chongqing, China; Lanzhou, China · 18 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results.
Desai J, Deva S, Gao B, et al. · Cancer Chemother Pharmacol 2025
- BGB-A445, a novel non-ligand-blocking agonistic anti-OX40 antibody, exhibits superior immune activation and antitumor effects in preclinical models.
Jiang B, Zhang T, Deng M, et al. · Front Med 2023
Also in development for Urothelial Carcinoma
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- 9MW2821Phase 311 trials
Mabwell (Shanghai) Bioscience Co., Ltd. · Urothelial Carcinoma, Advanced Urothelial Carcinoma, Locally Advanced or Metastatic Triple-negative Breast Cancer
- CetrelimabJNJ-63723283Phase 38 trials
Johnson & Johnson (Janssen) · Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms
- BudigalimabABBV-181Phase 36 trials
AbbVie · Hepatocellular Carcinoma, Non Small Cell Lung Carcinoma, c-MET
- SYS6002Phase 35 trials
CSPC Megalith Biopharmaceutical Co.,Ltd. · Urothelial Carcinoma, Cervical Cancer, Advanced Solid Tumors
- Cretostimogene GrenadenorepvecCG0070Phase 34 trials
CG Oncology, Inc. · Non Muscle Invasive Bladder Cancer, High-grade Ta/ T1 Papillary Disease Bladder Cancer, Urologic Cancer
- LivmoniplimabABBV-151Phase 34 trials
AbbVie · Hepatocellular Carcinoma, Urothelial Carcinoma, Non-Small Cell Lung Cancer
- SI-B003Phase 210 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Squamous Cell Carcinoma of Head and Neck
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from BeOne Medicines (BeiGene).
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.